Meta Pharmaceuticals, a corporation specializing in pharmaceuticals and medical devices manufacturing and research and development (R&D), is targeting the global implant market.
Meta Pharmaceuticals announced on the 14th that it has acquired the management rights equity of dental implant manufacturer EZEN Implant, integrating it as a wholly owned subsidiary.
Through the acquisition of EZEN Implant, Meta Pharmaceuticals has expanded its lineup of medical devices research and development and manufacturing, including lifting procedure polydioxanone absorbable sutures (lifting threads), hair transplantation devices, and dental implants.
EZEN Implant is a dental implant corporation established in 2016. From its inception, it has been pursuing a global market entry strategy and currently exports implants to 19 countries worldwide, including Russia, Vietnam, and India. EZEN Implant holds U.S. Food and Drug Administration (FDA) and European Conformity (CE) certifications, as well as six patented technologies.
Lee Su-jin, representative of Meta Pharmaceuticals, noted, "Through the acquisition of EZEN Implant, we have strengthened our capabilities in medical device manufacturing and research and development and secured long-term growth momentum as an implant manufacturing corporation."
Meta Pharmaceuticals recorded sales and operating profit of 32.5 billion won and 7.1 billion won, respectively, last year. This represents an increase of 58% and 152% compared to the previous year.